AMPHQT73Amphastar Pharmaceuticals, Inc.·NASDAQ
27.03-2.49%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E15.99EPS (ttm)1.69Insider Own14.52%Shs Outstand42.54MPerf Week6.12%
Market Cap1.15BForward P/E8.52EPS next Y3.17Insider Trans-0.54%Shs Float31.29MPerf Month6.29%
Enterprise Value1.54BPEG11.50EPS next Q0.86Short Float13.85%Perf Quarter35.83%
Income77.00MP/S1.58EPS this Y-13.86%Short Ratio9.12Perf Half Y18.87%
Sales730.00MP/B1.50EPS next Y7.09%ROA4.50%Short Interest4.33MPerf YTD0.93%
Book/sh18.05P/C3.96EPS next 5Y1.39%ROE10.11%52W High29.52 -8.43%Perf Year9.61%
Cash/sh6.82P/FCF7.52EPS past 3/5Y5.27% 134.54%ROIC5.90%52W Low16.65 62.34%Perf 3Y-39.85%
Dividend Est.—EV/EBITDA8.01Sales past 3/5Y13.00% 15.52%Gross Margin47.68%Volatility3.01% 3.17%Perf 5Y41.52%
Dividend TTM—EV/Sales2.11EPS Y/Y TTM-36.70%Oper. Margin15.66%ATR (14)0.86Perf 10Y45.40%
Dividend Ex-DateJun 11, 2010Quick Ratio1.71Sales Y/Y TTM1.25%Profit Margin10.76%RSI (14)59.80Recom2.83
Dividend Gr. 3/5Y—Current Ratio2.40EPS Q/Q7.06%SMA203.25%Beta0.93Target Price21.00
Payout0.00%Debt/Eq0.88Sales Q/Q5.75%SMA508.67%Rel Volume1.07Prev Close27.72
Employees1,976LT Debt/Eq0.88EarningsNov 05SMA20021.47%Avg Volume467.21KPrice27.03
IPO DateJun 25, 2014Option/ShortYes / YesEPS/Sales Surpr.46.75% 2.21%Net Debt/EBITDA2.03Volume497,700Change-2.49%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-18-26ReiteratedBarclaysEqual Weight$20 → $23
Jun-29-26DowngradeB of A SecuritiesNeutral → Underperform
Jun-03-26ReiteratedBarclaysEqual Weight$30 → $20
May-14-26DowngradeWells FargoOverweight → Equal Weight$19
May-11-26ReiteratedPiper SandlerNeutral$32 → $21
May-08-26DowngradeNeedhamBuy → Hold
Apr-21-26DowngradeJefferiesBuy → Hold$22
Dec-08-25InitiatedBarclaysEqual Weight$30
Aug-12-25UpgradeNeedhamHold → Buy
May-12-25DowngradeJP MorganOverweight → Neutral
Latest News· Times ET
Oct-29-26
Oct-28-26
Oct-16-26
Oct-08-26
Oct-06-26
Sep-30-26
Sep-21-26
Sep-20-26
Sep-06-26
Sep-01-26
Aug-27-26
Aug-24-26
Company

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue730720732644—————
Cost of Goods Sold Incl. D&A381364358293—————
Gross Profit348356374351—————
Selling, General and Administrative Excl. Other1401309580—————
Research and Development94867474—————
Other Operating Expense00-10—————
Operating Income115140205197—————
Interest Expense27253027—————
Unusual Expense
—————————
Non-Operating Income (Expense)139140—————
Net Income Before Taxes103124189169—————
Income Taxes23263032—————
Consolidated Net Income7798160138—————
Net Income From Continuing Operations7798160138—————
Net Income7798160138—————
EPS (Recurring)1.742.103.292.85—————
EPS (Basic, Before Extraordinaries)1.742.103.292.85—————
EPS (Diluted)1.692.033.062.60—————
EBITDA192212277240—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio15.9913.1912.1323.79—————
Price To Sales Ratio1.631.752.434.61—————
Gross Margin47.6749.4451.0954.50—————
Operating Margin15.7519.4428.0130.59—————
Net Margin10.5513.6121.8621.43—————
Shares Outstanding44474848—————
Market Capitalization1,1891,2591,7822,969—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$32.90$28.37$23.84$19.31$14.78● Close Price0.00K141.93K283.86K425.79K567.72KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
PETERS WILLIAM JCFO, EVP & TREASURERSep 21 '26Sale25.004,139103,475168,707Sep 23
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 16 '26Sale23.9410,000239,404169,203Sep 17
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 16 '26Option Exercise13.3510,000133,500179,203Sep 17
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 02 '26Sale23.633,18775,306169,203Sep 03
PRINS RICHARD KDirectorAug 11 '26Sale20.307,973161,85229,625Aug 12
PETERS WILLIAM JCFO, EVP & TREASURERAug 07 '26Option Exercise19.795,05399,999181,026Aug 11
PETERS WILLIAM JCFO, EVP & TREASURERAug 07 '26Sale22.488,180183,886172,846Aug 11
Zhou RongSENIOR EVP, PRODUCTION CENTERDec 17 '25Option Exercise11.339,787110,887147,830Dec 18
Zhou RongSENIOR EVP, PRODUCTION CENTERDec 17 '25Sale26.209,787256,379138,043Dec 18
Petersen Floyd F.DirectorDec 12 '25Sale25.922,42662,88871,368Dec 15
Petersen Floyd F.DirectorDec 11 '25Sale25.691,73744,62073,794Dec 15
PRINS RICHARD KDirectorNov 25 '25Option Exercise16.694,17969,74839,362Nov 25
PRINS RICHARD KDirectorNov 25 '25Sale27.104,179113,25335,183Nov 25
Petersen Floyd F.DirectorNov 13 '25Option Exercise16.6916,679278,37392,210Nov 17
Petersen Floyd F.DirectorNov 13 '25Sale26.4916,679441,83775,531Nov 17
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.